Literature DB >> 20592741

Sipuleucel-T.

Celestia S Higano, Eric J Small, Paul Schellhammer, Uma Yasothan, Steven Gubernick, Peter Kirkpatrick, Philip W Kantoff.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20592741     DOI： 10.1038/nrd3220

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  10 in total

1.  Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Authors:  E J Small; P Fratesi; D M Reese; G Strang; R Laus; M V Peshwa; F H Valone
Journal:  J Clin Oncol       Date:  2000-12-01       Impact factor: 44.544

Review 2.  The promise of cancer vaccines.

Authors:  Eli Gilboa
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

3.  Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Authors:  Eric J Small; Paul F Schellhammer; Celestia S Higano; Charles H Redfern; John J Nemunaitis; Frank H Valone; Suleman S Verjee; Lori A Jones; Robert M Hershberg
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

4.  Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Authors:  P A Burch; J K Breen; J C Buckner; D A Gastineau; J A Kaur; R L Laus; D J Padley; M V Peshwa; H C Pitot; R L Richardson; B J Smits; P Sopapan; G Strang; F H Valone; S Vuk-Pavlović
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

5.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Authors:  William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 8.  Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.

Authors:  Punam H Patel; Denise R Kockler
Journal:  Ann Pharmacother       Date:  2007-12-19       Impact factor: 3.154

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.

Authors:  Brian Schurko; William K Oh
Journal:  Nat Clin Pract Oncol       Date:  2008-07-22
  10 in total
  56 in total

1.  Cabazitaxel.

Authors:  Matthew D Galsky; Argyris Dritselis; Peter Kirkpatrick; William K Oh
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

2.  A needle in the 'cancer vaccine' haystack.

Authors:  Anne Gallois; Nina Bhardwaj
Journal:  Nat Med       Date:  2010-08       Impact factor: 53.440

3.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Authors:  Luc Pilotte; Pierre Larrieu; Vincent Stroobant; Didier Colau; Eduard Dolusic; Raphaël Frédérick; Etienne De Plaen; Catherine Uyttenhove; Johan Wouters; Bernard Masereel; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 4.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

5.  Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis.

Authors:  Lei Wang; Wenfang Li; Muqing Lin; Monika Garcia; David Mulholland; Michael Lilly; Manuela Martins-Green
Journal:  Carcinogenesis       Date:  2014-07-14       Impact factor: 4.944

Review 6.  The changing therapeutic landscape of castration-resistant prostate cancer.

Authors:  Timothy A Yap; Andrea Zivi; Aurelius Omlin; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

7.  Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.

Authors:  Lei Wang; Jeffrey Ho; Carlotta Glackin; Manuela Martins-Green
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 8.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04

Review 9.  Cellular and vaccine therapeutic approaches for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate L Erickson; Martin R Jadus; Robert M Prins; Linda M Liau; Carol A Kruse
Journal:  J Transl Med       Date:  2010-10-14       Impact factor: 5.531

Review 10.  Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.

Authors:  Catherine E Handy; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2017-12-20       Impact factor: 3.404
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.